Table 3.

Risk of Infection in Strata of HPV16 cLIA and HPV16 VLP ELISA in 933 Women

		No. (%) of participants
VLP ELISA	cLIA	HPV16−	HPV16+	CIN2+ HPV16	Total	OR (95% CI) for any HPV16
Neg	Neg	602 (82.0)	113 (15.4)	19 (2.6)	734	Ref
	Pos	17 (85.0)	3 (15.0)	0	20	0.81 (0.23–2.79)
Pos	Neg	91 (86.7)	12 (11.4)	2 (1.9)	105	0.70 (0.39–1.27)
	Pos	69 (93.2)	5 (6.8)	0	74	0.33 (0.13–0.84)

NOTE. CI, confidence interval; CIN2+ HPV16, concurrent detection of CIN2 or greater and HPV16; cLIA, competitive Luminex Immunoassay; HPV, human papillomavirus; HPV16−, negative for HPV16 in follow-up; HPV16+, positive for HPV16 in follow-up but no CIN2+ related to HPV16; Neg, negative; OR, odds ratio adjusted for continuous age at enrollment; Pos, positive; VLP ELISA, virus-like particle enzyme-linked immunosorbent assay.